ArticleRSC advances2018
Thymoquinone protects against cardiac damage from doxorubicin-induced heart failure in Sprague-Dawley rats.
Article in RSC advances, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- Effect of Nigella sativa and its bioactive compound on type 2 epithelial to mesenchymal transition: a systematic review.BMC complementary and alternative medicine · 2019Pooled it
- Protective Effects of Vitamin D Against Doxorubicin Chemotherapy-Induced Hepatotoxicity in Wistar Albino Rats: Evidence fromNutrients · 2026Article
- Effect of thymoquinone on transient receptor potential melastatin (TRPM) channels in rats with liver ischemia reperfusion model in rats.Iranian journal of basic medical sciences · 2024Article
- p53 at the Crossroads between Doxorubicin-Induced Cardiotoxicity and Resistance: A Nutritional Balancing Act.Nutrients · 2023Review
- Vagus nerve stimulation exerts cardioprotection against doxorubicin-induced cardiotoxicity through inhibition of programmed cell death pathways.Cellular and molecular life sciences : CMLS · 2022Article
- Thymoquinone dose-dependently attenuates myocardial injury induced by isoproterenol in rats via integrated modulations of oxidative stress, inflammation, apoptosis, autophagy, and fibrosis.Naunyn-Schmiedeberg's archives of pharmacology · 2021Article
- Article
- Review
- Engineering of Doxorubicin-Encapsulating and TRAIL-Conjugated Poly(RGD) Proteinoid Nanocapsules for Drug Delivery Applications.Polymers · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure is a complex end stage result of various cardiovascular diseases, and has a poor prognosis. The mechanisms for the development and progression of heart failure have always been an important topic in cardiovascular research, and previous studies have shown that thymoquinone (TQ) protects against cardiotoxicity and cardiac damage. The aim of this study was to investigate the possible protective effects of thymoquinone against cardiac damage in doxorubicin (DOX)-induced heart failure in Sprague-Dawley Rats (SDR). Forty-five male SDR were randomly divided into three groups and administered different treatment regimens for 8 weeks. Left ventricular fractional shortening (LVFS) and ejection fraction (LVEF) were higher in the DOX + TQ group than those in the DOX group. Significant pathophysiology changes (HE and Masson staining) were observed in rats of the DOX group compared to those of the DOX + TQ group. The addition of Thymoquinone inhibited DOX-induced cardiac fibrosis (TGF-β, Smad3, collagen I, collagen III, and α-SMA) and apoptosis (P53, bcl-2, caspase-3, caspase-9, and BAX) in SDR, indicating that thymoquinone may be a potential therapeutic target for cardiac damage caused by DOX-induced heart failure.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.